[Durvalumab (NSCLC) – Benefit assessment according to §35a Social Code Book V]
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018005096
German
Original Title:
Tremelimumab und Durvalumab (NSCLC)
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a23-31.html
Year Published:
2023
URL for published report:
https://www.iqwig.de/download/a23-29-und-a23-31_tremelimumab-und-durvalumab_nutzenbewertung-35a-sgb-v_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Antibodies, Monoclonal
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Antineoplastic Combined Chemotherapy Protocols
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents, Immunological
Keywords
- Durvalumab
- Tremelimumab
- Carcinoma – Non-Small-Cell Lung
- Benefit Assessment
- NCT03164616
- NCT02142738
- NCT02220894
- NCT03215706
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.